ap

[ASAP] Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00601




ap

[ASAP] Chimeric Peptidomimetics of SOCS 3 Able to Interact with JAK2 as Anti-inflammatory Compounds

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00664




ap

[ASAP] Progress in the Field of Aldehyde Dehydrogenase Inhibitors: Novel Imidazo[1,2-<italic toggle="yes">a</italic>]pyridines against the 1A Family

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00686




ap

[ASAP] Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinases Alpha and Zeta

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00118




ap

[ASAP] Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00116




ap

[ASAP] Glycans Meet Sphingolipids: Structure-Based Design of Glycan Containing Analogues of a Sphingosine Kinase Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00665




ap

[ASAP] Peptoid NPhe<sup>4</sup> in AGRP-Based c[Pro<sup>1</sup>-Arg<sup>2</sup>-Phe<sup>3</sup>-Phe<sup>4</sup>-Xxx<sup>5</sup>-Ala<sup>6</sup>-Phe<sup>7</sup>

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00641




ap

[ASAP] Therapeutic Potential of Targeted Nanoparticles and Perspective on Nanotherapies

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00075




ap

[ASAP] Synthesis of Novel G Factor or Chloroquine-Artemisinin Hybrids and Conjugates with Potent Antiplasmodial Activity

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00669




ap

[ASAP] Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00043




ap

[ASAP] Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00045




ap

[ASAP] Substituted Naphthalenediimide Compounds Bind Selectively to Two Human Quadruplex Structures with Parallel Topology

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00041




ap

[ASAP] Escaping from Flatland: Substituted Bridged Pyrrolidine Fragments with Inherent Three-Dimensional Character

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00039




ap

[ASAP] Characterization of an Alginate Encapsulated LS180 Spheroid Model for Anti-colorectal Cancer Compound Screening

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00076




ap

[ASAP] Structure Optimization of Gatastatin for the Development of ?-Tubulin-Specific Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00526




ap

[ASAP] Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00625




ap

[ASAP] Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00111




ap

[ASAP] Assembling Pharma Resources to Tackle Diseases of Underserved Populations

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00051




ap

[ASAP] Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00639




ap

[ASAP] Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00681




ap

[ASAP] Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR?t Inverse Agonist

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00063




ap

[ASAP] Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00594




ap

[ASAP] New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00561




ap

[ASAP] Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00129




ap

[ASAP] Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00574




ap

[ASAP] Design and Synthesis of Tetrazole- and Pyridine-Containing Itraconazole Analogs as Potent Angiogenesis Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00438




ap

[ASAP] Potential Cancer Treatment by Agonists of the Stimulator of Interferon Genes

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00117




ap

[ASAP] Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00131




ap

[ASAP] Complete Regression of Carcinoma via Combined C-RAF and EGFR Targeted Therapy

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00159




ap

[ASAP] Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00008




ap

[ASAP] Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, In Silico, and Biological Evaluation

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00661




ap

[ASAP] Characterization of Specific <italic toggle="yes">N</italic>-a-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00029




ap

[ASAP] Discovery of an Atropisomeric PI3Kß Selective Inhibitor through Optimization of the Hinge Binding Motif

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00095




ap

[ASAP] Can Drug Repositioning Work as a Systematical Business Model?

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00122




ap

[ASAP] Update to Our Reader, Reviewer, and Author Communities—April 2020

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00206




ap

[ASAP] Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00155




ap

[ASAP] PROTAC Compounds Targeting a-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer’s and Parkinson’s Diseases

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00192




ap

[ASAP] Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from <italic toggle="yes">Trypanosoma cruzi</italic>

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00106




ap

[ASAP] P2Y<sub>14</sub> Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00115




ap

[ASAP] Discovery of RO7185876, a Highly Potent ?-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer’s Disease

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00109




ap

[ASAP] Ultra-High-Throughput Acoustic Droplet Ejection-Open Port Interface-Mass Spectrometry for Parallel Medicinal Chemistry

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00066




ap

[ASAP] Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00025




ap

[ASAP] Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00092




ap

[ASAP] Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 d Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00028




ap

[ASAP] Development of a Raltegravir-based Photoaffinity-Labeled Probe for Human Immunodeficiency Virus-1 Integrase Capture

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00009




ap

[ASAP] Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00085




ap

[ASAP] De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00022




ap

[ASAP] Synthesis and Evaluation of <sup>11</sup>C- and <sup>18</sup>F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00127




ap

[ASAP] Ligand Design for Cereblon Based Immunomodulatory Therapy

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00214




ap

Popular Design News of the Week: April 20, 2020 – April 26, 2020

Every week users submit a lot of interesting stuff on our sister site Webdesigner News, highlighting great content from around the web that can be of interest to web designers.  The best way to keep track of all the great stories and news being posted is simply to check out the Webdesigner News site, however, […]